Selling, General, and Administrative Costs: AbbVie Inc. vs Biogen Inc.

A Tale of Two Giants: AbbVie Inc. vs Biogen Inc.

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. Over the past decade, AbbVie Inc. and Biogen Inc. have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, AbbVie Inc. experienced a staggering 98% increase in SG&A costs, peaking in 2022. This surge reflects their aggressive expansion and marketing strategies. In contrast, Biogen Inc.'s SG&A expenses remained relatively stable, with only a 14% increase over the same period, indicating a more conservative approach.

Key Insights

• AbbVie Inc.: Notable for its significant rise in SG&A expenses, particularly from 2020 onwards.
• Biogen Inc.: Maintained a steady trajectory, with minor fluctuations.

These trends highlight the diverse strategies employed by these pharmaceutical giants, offering valuable insights into their operational priorities.